Covers various monomers such as sugar ring modifications (e.g., 2’-OMe/MOE/F, 3’-NH2, LNA, Succinates), base modifications, phosphate backbone modifications (e.g., thiolation, PMO, PNA) and functional group modifications. It is also complemented by ligand monomers like GalNac, supporting high-purity, large-scale and stable supply.

Includes mainstream types such as miRNA, siRNA, sgRNA and ASO, as well as oligonucleotide-peptide, liposome, GalNac, toxin conjugates. Customization from milligram to hectogram scale is achievable.

- Independent design and development capabilities for modified monomers (sugar ring, base, backbone modifications) and customer-customized products.

- Possesses large-scale monomer production capacity, providing multi-specification and high-quality products on demand.

- Synergy between small building block technology and monomer synthesis enhances efficiency and reduces costs, delivering cost-competitive raw materials for downstream processes.

- Utilizes solid-phase phosphoramidite chemistry and enzymatic ligation processes to efficiently complete oligonucleotide sample synthesis and process development, meeting diverse scenario requirements.

- Equipped with equipment such as OP100, OligoSynt, AKTA Pure, TFF and high-throughput synthesizers, supporting the scale-up from milligram-level R&D samples to hectogram-level production to adapt to full-stage needs; pilot plant is under planning.

- Complies with GMP standards, equipped with detection systems such as HPLC, LC-MS and MALDI-TOF. Purity, impurities and other indicators are monitored throughout the process, meeting global regulatory filing requirements.